Amgen will offer its lipid-lowering drug Repatha directly to patients for $239 per month, representing a nearly 60% reduction ...

Eligible Patients Can Access Repatha at Nearly 60% Discount From the List Price THOUSAND OAKS, Calif., Oct. 6, 2025 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced ...

Amgen on Monday launched direct-to-consumer U.S. sales of its cholesterol medication Repatha at a discounted cash price, ...

Thursday, October 23, 2025 The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Amazon.com ...

Amgen (AMGN) announced on Monday that eligible patients can access its drug Repatha at about a 60% discount from the list price via its direct-to-patient program. The program, called AmgenNow, follows ...

Amgen Inc. (NASDAQ:AMGN) is included among the 11 Defensive Healthcare Dividend Stocks to Buy Now. Amgen Inc. (NASDAQ:AMGN) ...

In today's Pharmalittle roundup, we're reading about Novo Nordisk layoffs, an Amgen discount program, and more.

GoodRx, an online platform that offers drug discount coupons to patients, is in talks with the government to participate in ...

In alignment with the Trump administration’s efforts to lower drug prices, Amgen today launched AmgenNow, a direct-to-patient program offering evolocumab (Repatha) at a monthly price of $239, nearly ...

As the Trump administration makes pacts with pharmaceutical manufacturers, consumers need more transparency about who is ...

Trump’s focus on lowering drug prices targets a critical issue for Americans. But without far greater transparency, it’s ...

Amgen (NASDAQ:AMGN) announced on Thursday that its PCSK9 inhibitor Repatha (evolocumab) reached the primary endpoints in a Phase 3 trial designed to evaluate its effect in reducing major adverse ...